| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-147-10-200711200-00003 |
| P698 | PubMed publication ID | 18025443 |
| P50 | author | Michael Manns | Q1564831 |
| Stefan Zeuzem | Q28360321 | ||
| Bettina Hansen | Q40007319 | ||
| Heiner Wedemeyer | Q88161344 | ||
| P2093 | author name string | E Jenny Heathcote | |
| Solko W Schalm | |||
| Harry L A Janssen | |||
| Bart J Veldt | |||
| W Peter Hofmann | |||
| Juerg Reichen | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| hepatitis C | Q154869 | ||
| patient | Q181600 | ||
| chronic hepatitis C | Q55779873 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 677-684 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. | |
| P478 | volume | 147 |
| Q37229672 | A Canadian screening program for hepatitis C: is now the time? |
| Q36029791 | A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP. |
| Q57826499 | A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities |
| Q45360205 | A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis |
| Q59475778 | A new paradigm evaluating cost per cure of HCV infection in the UK |
| Q37862076 | A new standard of care for the treatment of chronic HCV infection |
| Q43039814 | A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. |
| Q33394104 | A review of the treatment of chronic hepatitis C virus infection in cirrhosis |
| Q89678509 | Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment - preliminary report |
| Q38314738 | Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease? |
| Q83578903 | Advanced chronic hepatitis C: how to handle if you cannot halt? |
| Q37345951 | Advances in prevention and diagnosis of hepatocellular carcinoma |
| Q38161848 | After the cure: management of HCV after achievement of SVR. |
| Q33413353 | All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. |
| Q42251203 | All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses |
| Q35100139 | An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver |
| Q30453975 | An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver |
| Q24632766 | An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases |
| Q37738637 | Antifibrotic therapies: will we ever get there? |
| Q37749115 | Antiviral therapy for hepatitis C: why are so few patients being treated? |
| Q37630394 | Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation |
| Q37158382 | Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin |
| Q34913362 | Barriers to accessing care in patients with chronic hepatitis C: the impact of depression |
| Q34926607 | Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis |
| Q41480323 | Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms |
| Q38014499 | Basic answers to complicated questions for the course of chronic hepatitis C treatment |
| Q28546936 | Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study |
| Q42989479 | Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis |
| Q35180503 | Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis |
| Q41703119 | Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade |
| Q38797618 | Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening |
| Q56929229 | Chronic hepatitis C |
| Q26775011 | Chronic hepatitis C: This and the new era of treatment |
| Q98386855 | Clinical impact of normal alanine aminotransferase on direct-acting antiviral outcome in patients with chronic hepatitis C virus infection |
| Q36112998 | Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in Northern California |
| Q51643325 | Clinical trials and their translation in hepatology: past, present, and future. |
| Q27489398 | Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients |
| Q37279232 | Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. |
| Q57119487 | Clinicopathologic characteristics andoutcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection |
| Q37403606 | Collagen-binding vascular endothelial growth factor attenuates CCl4-induced liver fibrosis in mice |
| Q39438394 | Comments on cochrane review on direct-acting antivirals for hepatitis C. |
| Q43615259 | Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers |
| Q51808016 | Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. |
| Q41434717 | Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. |
| Q45050419 | Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. |
| Q40584662 | Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients |
| Q37365467 | Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil |
| Q36115516 | Cost-effectiveness and population outcomes of general population screening for hepatitis C. |
| Q37484155 | Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population |
| Q28540562 | Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C |
| Q38206573 | Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature |
| Q38295834 | Cure of HCV related liver disease |
| Q34036762 | Current and future therapies for hepatitis C virus infection |
| Q35999496 | Current standards in the treatment of chronic hepatitis C. |
| Q40960952 | Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison |
| Q42981494 | Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial |
| Q61444348 | Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q29619682 | Diagnosis, management, and treatment of hepatitis C: an update |
| Q37663921 | Direct-acting antiviral agents in patients with hepatitis C cirrhosis |
| Q39009632 | Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs |
| Q38548066 | Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. |
| Q43042207 | Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus |
| Q38630475 | Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. |
| Q42992596 | Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral |
| Q38589516 | Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. |
| Q43000439 | Editorial : Treatment of Patients With HCV-Related Cirrhosis With Peginterferon and Ribavirin: Swinging the Pendulum Toward Treatment |
| Q40279496 | Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population |
| Q37174403 | Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. |
| Q41084425 | Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans |
| Q42947251 | Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection |
| Q42855168 | Effect of hepatic iron concentration and viral factors in chronic hepatitis C-infected patients with thalassemia major, treated with interferon and ribavirin |
| Q42202049 | Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C. |
| Q40328514 | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study |
| Q38402939 | Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease. |
| Q42992774 | Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis |
| Q39640069 | Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. |
| Q34533176 | Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis |
| Q38233602 | Efficacy of daclatasvir in hepatitis C virus |
| Q34577107 | Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting |
| Q39008634 | Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. |
| Q43034847 | Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. |
| Q36618416 | Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study |
| Q35201293 | Evidence-based clinical guidelines for immigrants and refugees |
| Q89923822 | Extrahepatic manifestations in hepatitis C virus infection |
| Q57128381 | Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: A meta-analysis |
| Q43271371 | Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. |
| Q27009321 | Future classes of hepatitis C virus therapeutic agents |
| Q30235178 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C |
| Q34243993 | Future treatment of patients with HCV cirrhosis |
| Q37077112 | Global control of hepatitis C: where challenge meets opportunity |
| Q37417999 | Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design |
| Q35090634 | HCV and HIV co-infection: mechanisms and management. |
| Q41703740 | HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. |
| Q64244966 | HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents |
| Q36484980 | Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. |
| Q43079078 | Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma |
| Q59352655 | Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
| Q91801771 | Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
| Q41103902 | Hepatitis C Virus Therapy-related Skin Manifestations. |
| Q42991359 | Hepatitis C drug development at a crossroads |
| Q34044333 | Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus |
| Q41758808 | Hepatitis C in African Americans |
| Q30378509 | Hepatitis C treatment: where are we now? |
| Q38933599 | Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era. |
| Q33929521 | Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965 |
| Q37042440 | Hepatitis C virus vaccines among people who inject drugs |
| Q42987514 | Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. |
| Q44199367 | Hepatitis C virus: 25 years-old, the end? |
| Q83992415 | Hepatitis C: new therapeutic strategies needed for advanced disease |
| Q26765433 | Hepatitis Vaccines |
| Q26795750 | Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy |
| Q41412067 | High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation |
| Q37025212 | Highly active anti-hepatitis C therapy: seven lessons from HIV. |
| Q43047576 | Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis |
| Q39793127 | How to use virological tools for the optimal management of chronic hepatitis C. |
| Q39815361 | Humanistic and economic impacts of hepatitis C infection in the United States |
| Q41987277 | IDSA/AASLD response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. |
| Q36935025 | IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS. |
| Q58095372 | Identifying barriers to treatment of HCV in the primary care setting |
| Q58723499 | Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study |
| Q37970381 | Immunosuppression, liver injury and post-transplant HCV recurrence |
| Q56980591 | Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S |
| Q36334385 | Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. |
| Q35099749 | Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C. |
| Q35105799 | Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease |
| Q40534129 | Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model |
| Q34271143 | Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis |
| Q40238687 | Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. |
| Q41065311 | Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies |
| Q34677310 | Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study |
| Q41924669 | Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network |
| Q37112127 | Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease |
| Q58376682 | Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus |
| Q42382462 | Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. |
| Q36745162 | Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study |
| Q26996668 | Interferon induced IFIT family genes in host antiviral defense |
| Q34876460 | Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. |
| Q37288393 | Interferon-based therapy for chronic hepatitis C: current and future perspectives |
| Q35226081 | Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study |
| Q42938347 | Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle |
| Q40108102 | Is response-guided therapy being applied in the clinical setting? The hepatitis C example |
| Q38685569 | Is the benefit of treating patients with cirrhosis proven? |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q42271736 | Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults |
| Q99558446 | Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study |
| Q41429836 | Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). |
| Q41366537 | Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States |
| Q30244361 | Limiting the access to direct-acting antivirals against HCV: an ethical dilemma |
| Q50555735 | Liver stiffness diminishes with antiviral response in chronic hepatitis C. |
| Q42977116 | Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis |
| Q36067389 | Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. |
| Q34415157 | Long-term effects of antiviral therapy in patients with chronic hepatitis C. |
| Q84331255 | Long-term effects of sustained virologic response on the development of esophageal varices in compensated cirrhosis: "is the bang worth the buck?" |
| Q83354124 | Long-term low-dose maintenance pegylated interferon may prevent decompensation in cirrhotic patients with portal hypertension: are we there yet? |
| Q36769099 | Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy |
| Q34521418 | Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin |
| Q38097858 | Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal |
| Q38433971 | Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin |
| Q41465071 | MEDICINE. Global control of hepatitis C virus |
| Q36984871 | Management algorithm for genotype 1 hepatitis C virus |
| Q33427048 | Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies |
| Q37801596 | Management of Untreated and Nonresponder Patients with Chronic Hepatitis C |
| Q37194817 | Management of chronic hepatitis C in veterans: the potential of integrated care models |
| Q37627336 | Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin |
| Q44074214 | Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis |
| Q90724782 | Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis |
| Q29619336 | Mechanisms of hepatic fibrogenesis |
| Q45381877 | Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. |
| Q34081750 | NDRG2 ameliorates hepatic fibrosis by inhibiting the TGF-β1/Smad pathway and altering the MMP2/TIMP2 ratio in rats |
| Q33559298 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa |
| Q51817207 | Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. |
| Q83335877 | Noninvasive measurement of liver fibrosis by transient elastography and influencing factors in patients with chronic hepatitis B-A single center retrospective study of 466 patients |
| Q34700417 | Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis |
| Q38371479 | Occult hepatitis C virus infection and its relevance in clinical practice |
| Q33395436 | Occult hepatitis C: how convincing are the current data? |
| Q27490760 | On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula |
| Q39438895 | Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV-Coinfected Patients in Clinical Practice |
| Q33855483 | Optimizing the dose and duration of therapy for chronic hepatitis C. |
| Q34101701 | Outcome of sustained virological responders with histologically advanced chronic hepatitis C. |
| Q40399586 | Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism. |
| Q34521371 | Peginterferon and ribavirin treatment for hepatitis C virus infection |
| Q42999160 | Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response |
| Q42656554 | Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study |
| Q41819698 | Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea |
| Q38238013 | Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: out with the old, in with the new. |
| Q41142938 | Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir |
| Q45348539 | Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force |
| Q48035268 | Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study |
| Q45351981 | Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks |
| Q40281588 | Prediction of recurrence following hepatectomy in patients with hepatitis C virus infection-related hepatocellular carcinoma who achieved a sustained virological response. |
| Q42991926 | Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension |
| Q38323723 | Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs |
| Q37265614 | Preventative hepatology: minimising symptoms and optimising care. |
| Q64922011 | Protease inhibitors for the treatment of hepatitis C virus infection. |
| Q48721210 | Psychiatric side effects and fluctuations in serotonergic parameters in the treatment of chronic hepatitis C infection |
| Q39939298 | Public health impact of antiviral therapy for hepatitis C in the United States |
| Q35796138 | Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment. |
| Q37156704 | Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial |
| Q45323722 | Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. |
| Q40072782 | Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals |
| Q33430833 | Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis |
| Q26752433 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease |
| Q37397022 | Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. |
| Q37343311 | Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy |
| Q42238105 | Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. |
| Q36006322 | Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study |
| Q86022770 | Reply |
| Q38522791 | Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. |
| Q40111638 | Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection |
| Q37355850 | Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies |
| Q38974002 | Reversal of liver cirrhosis: current evidence and expectations |
| Q33731308 | Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? |
| Q37340946 | Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms |
| Q40542259 | Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation |
| Q33977173 | Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans |
| Q42988052 | Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. |
| Q39178715 | SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis |
| Q37347748 | Serum iron markers in patients with chronic hepatitis C infection |
| Q33406835 | Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review |
| Q38758591 | Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression? |
| Q36103046 | Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses |
| Q52657977 | Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication. |
| Q41535486 | Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. |
| Q42990108 | Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. |
| Q45378297 | Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study |
| Q34172595 | Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more |
| Q43240411 | Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. |
| Q45383108 | Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus |
| Q36841325 | Sustained virological response: a milestone in the treatment of chronic hepatitis C. |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q38096012 | Systematic review: Asian patients with chronic hepatitis C infection |
| Q37810315 | Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation |
| Q34522481 | Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis |
| Q39564809 | Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. |
| Q90611643 | The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study |
| Q38804947 | The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council |
| Q54217219 | The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. |
| Q34550098 | The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries |
| Q45357120 | The burden of untreated hepatitis C virus infection: a US patients' perspective |
| Q24657903 | The cost-effectiveness of Vancouver's supervised injection facility |
| Q38716514 | The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. |
| Q35231817 | The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. |
| Q39878799 | The healthcare burden imposed by liver disease in aging Baby Boomers |
| Q35590977 | The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection |
| Q57301376 | The impact of antiviral therapy on hepatocellular carcinoma epidemiology |
| Q38181631 | The impact of hepatitis C burden: an evidence-based approach. |
| Q55288229 | The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. |
| Q42990080 | The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy |
| Q45343893 | The ongoing debate of who to treat for chronic hepatitis C virus |
| Q38039401 | The race for interferon-free HCV therapies: a snapshot by the spring of 2012. |
| Q40654311 | The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study |
| Q37063664 | The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy |
| Q50177933 | The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. |
| Q38405059 | Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. |
| Q37299503 | Treating hepatitis C in the prison population is cost-saving |
| Q38163155 | Treatment as prevention and cure towards global eradication of hepatitis C virus |
| Q41087896 | Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin |
| Q33391761 | Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis |
| Q37693926 | Treatment of chronic hepatitis C in elderly patients |
| Q39526702 | Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir. |
| Q38460386 | Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy |
| Q36142732 | Treatment of patients with HCV related cirrhosis: many rewards with very few risks. |
| Q26771244 | Treatment strategies for chronic hepatitis C prior to and following liver transplantation |
| Q45330154 | Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office |
| Q37385551 | Use of specialty care versus standard retail pharmacies for treatment of hepatitis C. |
| Q34643724 | Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection |
| Q38265121 | Utility of evaluating HCV in an uninsured population |
| Q46076105 | Utilization and antiviral therapy in patients with chronic hepatitis C: analysis of ambulatory care visits in the US. |
| Q42285764 | Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin. |
| Q33593219 | Viral hepatitis and hepatocellular carcinoma: etiology and management |
| Q35928048 | Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir |
| Q27490841 | Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment |
| Q38569681 | What does the pharmacological future of treating chronic hepatitis C look like? |
| Q37314268 | When to treat and the benefits of treating hepatitis C in patients with haemophilia |
| Q42259157 | Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis |
| Q38685564 | Why do I treat my patients with mild hepatitis C? |
Search more.